The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Pseudomonas aeruginosa: Recent Advances in Vaccine Development
Abstract
Pseudomonas aeruginosa is an important opportunistic human pathogen. Using its arsenal of virulence factors and its intrinsic ability to adapt to new environments, P. aeruginosa causes a range of complicated acute and chronic infections in immunocompromised individuals. Of particular importance are burn wound infections, ventilator-associated pneumonia, and chronic infections in people with cystic fibrosis. Antibiotic resistance has rendered many of these infections challenging to treat and novel therapeutic strategies are limited. Multiple clinical studies using well-characterised virulence factors as vaccine antigens over the last 50 years have fallen short, resulting in no effective vaccination being available for clinical use. Nonetheless, progress has been made in preclinical research, namely, in the realms of antigen discovery, adjuvant use, and novel delivery systems. Herein, we briefly review the scope of P. aeruginosa clinical infections and its major important virulence factors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Foundational work on alginate conjugates and the OprF and OprI formulation IC43 shaped the field.”
From Understanding Pseudomonas aeruginosa Biofilms: Quorum Sensing, c-di-GMP Signaling, and Emerging Antibiofilm Approaches (2026) · cites this paper as [224]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tacconelli, E., Carrara, E., Savoldi, A., Harbarth, S., Mendelson, M., Monnet, D. L., Pulcini, C., Kahlmeter, G., Kluytmans, J., Carmeli, Y., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30753-3 · Cited by 6,142
Mechanisms of Antibiotic Resistance
Munita, J. M., & Arias, C. A. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.vmbf-0016-2015 · Cited by 2,782
Elborn, J. S. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00576-6 · Cited by 1,805
Co-infections in people with COVID-19: a systematic review and meta-analysis.
Lansbury, L., Lim, B., Baskaran, V., & Lim, W. S. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.05.046 · Cited by 1,619
Mechanisms of antibiotic resistance
Munita, J. M., & Arias, C. A. (2016) · Virulence Mechanisms of Bacterial Pathogens · doi:10.1128/9781555819286.ch17 · Cited by 421
Research works printed but not linked: 118
- Mulani, 2019, Emerging Strategies to Combat ESKAPE Pathogens in the Era of Antimicrobial Resistance: A Review, Front. Microbiol., 10, 539, 10.3389/fmicb.2019.00539 · DOI · Paper page
- Founou, R.C., Founou, L.L., and Essack, S.Y. (2017). Clinical and economic impact of antibiotic resistance in developing countries: A systematic review and meta-analysis. PLoS ONE, 12. · DOI · Paper page
- Moradali, 2017, Pseudomonas aeruginosa Lifestyle: A Paradigm for Adaptation, Survival, and Persistence, Front. Cell. Infect. Microbiol., 7, 39, 10.3389/fcimb.2017.00039 · DOI · Paper page
- Jurado-Martín, I., Sainz-Mejías, M., and McClean, S. (2021). Pseudomonas aeruginosa: An Audacious Pathogen with an Adaptable Arsenal of Virulence Factors. Int. J. Mol. Sci., 22. · DOI · Paper page
- Barken, 2008, Roles of type IV pili, flagellum-mediated motility and extracellular DNA in the formation of mature multicellular structures in Pseudomonas aeruginosa biofilms, Environ. Microbiol., 10, 2331, 10.1111/j.1462-2920.2008.01658.x · DOI · Paper page
- Deveaux, W., and Selvarajoo, K. (2019). Searching for simple rules in Pseudomonas aeruginosa biofilm formation. BMC Res. Notes, 12. · doi:10.1186/s13104-019-4795-x
- Thi, M.T., Wibowo, D., and Rehm, B.H.A. (2020). Pseudomonas aeruginosa Biofilms. Int. J. Mol. Sci., 21. · DOI · Paper page
- Moser, 2021, Immune Responses to Pseudomonas aeruginosa Biofilm Infections, Front. Immunol., 12, 625597, 10.3389/fimmu.2021.625597 · DOI · Paper page
- Zgurskaya, 2020, Molecular characterization of the outer membrane of Pseudomonas aeruginosa, Biochim. Et Biophys. Acta (BBA) Biomembr., 1862, 183151, 10.1016/j.bbamem.2019.183151 · DOI
- Pang, 2019, Antibiotic resistance in Pseudomonas aeruginosa: Mechanisms and alternative therapeutic strategies, Biotechnol. Adv., 37, 177, 10.1016/j.biotechadv.2018.11.013 · DOI · Paper page
- Breidenstein, 2011, Pseudomonas aeruginosa: All roads lead to resistance, Trends Microbiol., 19, 419, 10.1016/j.tim.2011.04.005 · DOI · Paper page
- Bisht, 2020, Pseudomonas aeruginosa polymicrobial interactions during lung infection, Curr. Opin. Microbiol., 53, 1, 10.1016/j.mib.2020.01.014 · DOI
- Raman, 2018, Risk factors for hospitalized patients with resistant or multidrug-resistant Pseudomonas aeruginosa infections: A systematic review and meta-analysis, Antimicrob. Resist. Infect. Control, 7, 79, 10.1186/s13756-018-0370-9 · DOI · Paper page
- Coates, M., Blanchard, S., and MacLeod, A.S. (2018). Innate antimicrobial immunity in the skin: A protective barrier against bacteria, viruses, and fungi. PLOS Pathog., 14. · DOI
- Elmassry, 2020, New markers for sepsis caused by Pseudomonas aeruginosa during burn infection, Metabolomics, 16, 40, 10.1007/s11306-020-01658-2 · DOI
- Mahar, 2010, Pseudomonas aeruginosa bacteraemia in burns patients: Risk factors and outcomes, Burns, 36, 1228, 10.1016/j.burns.2010.05.009 · doi:10.1016/j.burns.2010.05.009
- Weintrob, 2018, Early Infections Complicating the Care of Combat Casualties from Iraq and Afghanistan, Surg. Infect., 19, 286, 10.1089/sur.2017.240 · DOI
- Kollef, 2014, Global Prospective Epidemiologic and Surveillance Study of Ventilator-Associated Pneumonia due to Pseudomonas aeruginosa, Crit. Care Med., 42, 2178, 10.1097/CCM.0000000000000510 · DOI · Paper page
- Pitiriga, 2020, Central venous catheter-related bloodstream infection and colonization: The impact of insertion site and distribution of multidrug-resistant pathogens, Antimicrob. Resist. Infect. Control, 9, 189, 10.1186/s13756-020-00851-1 · DOI
- Olejnickova, 2014, Catheter-related infections caused by Pseudomonas aeruginosa: Virulence factors involved and their relationships, Pathog. Dis., 72, 87
- Safdar, 2005, Clinical and economic consequences of ventilator-associated pneumonia: A systematic review, Crit. Care Med., 33, 2184, 10.1097/01.CCM.0000181731.53912.D9 · DOI · Paper page
- Mehta, 2020, Bronchoscope-Related “Superbug” Infections, Chest, 157, 454, 10.1016/j.chest.2019.08.003 · doi:10.1016/j.chest.2019.08.003
- Baidya, 2021, Biofilm Formation by Pathogens Causing Ventilator-Associated Pneumonia at Intensive Care Units in a Tertiary Care Hospital: An Armor for Refuge, BioMed Res. Int., 2021, 8817700, 10.1155/2021/8817700 · DOI
- 2016, Pseudomonas aeruginosa in premise plumbing of large buildings, MicrobiologyOpen, 5, 937, 10.1002/mbo3.391 · DOI · Paper page
- Arancibia, 2002, Community-Acquired Pneumonia Due to Gram-Negative Bacteria and Pseudomonas aeruginosa: Incidence, Risk, and Prognosis, Arch. Intern. Med., 162, 1849, 10.1001/archinte.162.16.1849 · DOI · Paper page
- Kaier, K., Heister, T., Götting, T., Wolkewitz, M., and Mutters, N. (2019). Measuring the in-hospital costs of Pseudomonas aeruginosa pneumonia: Methodology and results from a German teaching hospital. BMC Infect. Dis., 19. · doi:10.1186/s12879-019-4660-5
- Restrepo, 2018, Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: A multinational point prevalence study of hospitalised patients, Eur. Respir. J., 52, 1701190, 10.1183/13993003.01190-2017 · DOI · Paper page
- Pressler, 2011, Chronic Pseudomonas aeruginosa infection definition: EuroCareCF Working Group report, J. Cyst. Fibros., 10, S75, 10.1016/S1569-1993(11)60011-8 · DOI · Paper page
- Rossi, 2021, Pseudomonas aeruginosa adaptation and evolution in patients with cystic fibrosis, Nat. Rev. Genet., 19, 331, 10.1038/s41579-020-00477-5 · DOI · Paper page
- Rau, 2010, Early adaptive developments of Pseudomonas aeruginosa after the transition from life in the environment to persistent colonization in the airways of human cystic fibrosis hosts, Environ. Microbiol., 12, 1643, 10.1111/j.1462-2920.2010.02211.x · DOI
- 2019, Pseudomonas aeruginosa in cystic fibrosis: A chronic cheater, Proc. Natl. Acad. Sci. USA, 116, 6525, 10.1073/pnas.1902734116 · doi:10.1073/pnas.1902734116
- Ehsan, 2015, Management of Pseudomonas aeruginosa infection in cystic fibrosis patients using inhaled antibiotics with a focus on nebulized liposomal amikacin, Futur. Microbiol., 10, 1901, 10.2217/fmb.15.117 · DOI
- Hartl, 2012, Innate immunity in cystic fibrosis lung disease, J. Cyst. Fibros., 11, 363, 10.1016/j.jcf.2012.07.003 · DOI · Paper page
- Toledano, 2019, Pseudomonas aeruginosa colonization causes PD-L1 overexpression on monocytes, impairing the adaptive immune response in patients with cystic fibrosis, J. Cyst. Fibros., 18, 630, 10.1016/j.jcf.2018.11.002 · DOI
- Costas, 2016, Specific immune response against Pseudomonas aeruginosa and haemophilus influenzae in severe COPD, Eur. Respir. J., 48, OA1790
- Kwok, 2021, Risk factors for Pseudomonas aeruginosa colonization in non-cystic fibrosis bronchiectasis and clinical implications, Respir. Res., 22, 132, 10.1186/s12931-021-01729-5 · DOI
- Fisher, 1970, Vaccination for Pseudomonas aeruginosa, Am. J. Surg., 120, 512, 10.1016/S0002-9610(70)80019-8 · doi:10.1016/s0002-9610(70)80019-8
- Young, 1973, Pseudomonas aeruginosa Vaccine in Cancer Patients, Ann. Intern. Med., 79, 518, 10.7326/0003-4819-79-4-518 · doi:10.7326/0003-4819-79-4-518
- Pennington, 1974, Preliminary Investigations of Pseudomonas aeruginosa Vaccine in Patients with Leukemia and Cystic Fibrosis, J. Infect. Dis., 130, S159, 10.1093/infdis/130.Supplement.S159 · doi:10.1093/infdis/130.supplement.s159
- Pennington, 1975, Use of a Pseudomonas aeruginosa vaccine in patients with acute leukemia and cystic fibrosis, Am. J. Med., 58, 629, 10.1016/0002-9343(75)90498-2 · doi:10.1016/0002-9343(75)90498-2
- Jones, 1976, A new Pseudomonas vaccine: Preliminary trial on human volunteers, J. Hyg., 76, 429, 10.1017/S0022172400055364 · doi:10.1017/s0022172400055364
- Elizabeth, 1983, Immunization of Burned Patients against Pseudomonas aeruginosa Infection at Safdarjang Hospital, New Delhi, Rev. Infect. Dis., 5, S922, 10.1093/clinids/5.Supplement_5.S922 · doi:10.1093/clinids/5.supplement_5.s922
- Langford, 1984, Prospective, controlled study of a polyvalent pseudomonas vaccine in cystic fibrosis--three year results, Arch. Dis. Child., 59, 1131, 10.1136/adc.59.12.1131 · doi:10.1136/adc.59.12.1131
- Cryz, 1987, Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans, J. Clin. Investig., 80, 51, 10.1172/JCI113062 · doi:10.1172/jci113062
- Cryz, 1988, Immunization with a Pseudomonas aeruginosa immunotype 5 O polysaccharide-toxin A conjugate vaccine: Effect of a booster dose on antibody levels in humans, Infect. Immun., 56, 1829, 10.1128/iai.56.7.1829-1830.1988 · doi:10.1128/iai.56.7.1829-1830.1988
- Schaad, 1991, Safety and immunogenicity of Pseudomonas aeruginosa conjugate A vaccine in cystic fibrosis, Lancet, 338, 1236, 10.1016/0140-6736(91)92103-9 · doi:10.1016/0140-6736(91)92103-9
- 2010, Prevention of Pseudomonas aeruginosa infection in cystic fibrosis patients, Int. J. Med Microbiol., 300, 573, 10.1016/j.ijmm.2010.08.010 · doi:10.1016/j.ijmm.2010.08.010
- Crowe, 1991, The First Clinical Trial of Immuno’s Experimental Pseudomonas aeruginosa Flagellar Vaccines, Pseudomonas Aeruginosa Hum. Dis., 44, 143
- Pfeiffer, 1995, Parenteral application of a Pseudomonas aeruginosa flagella vaccine elicits specific anti-flagella antibodies in the airways of healthy individuals, Am. J. Respir. Crit. Care Med., 151, 983
- Meisner, 2007, For the Flagella Vaccine Trial Study Group A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients, Proc. Natl. Acad. Sci. USA, 104, 11020, 10.1073/pnas.0702403104 · DOI · Paper page
- Pier, 1994, Human immune response to Pseudomonas aeruginosa mucoid exopolysaccharide (alginate) vaccine, Infect. Immun., 62, 3972, 10.1128/iai.62.9.3972-3979.1994 · DOI
- Cripps, 1997, Vaccine strategies against Pseudomonas aeruginosa infection in the lung, Behring Inst. Mitt., 98, 262
- Cripps, 2006, Safety and Immunogenicity of an Oral Inactivated Whole-Cell Pseudomonas aeruginosa Vaccine Administered to Healthy Human Subjects, Infect. Immun., 74, 968, 10.1128/IAI.74.2.968-974.2006 · doi:10.1128/iai.74.2.968-974.2006
- Mansouri, 1999, Safety and Immunogenicity of a Pseudomonas aeruginosa Hybrid Outer Membrane Protein F-I Vaccine in Human Volunteers, Infect. Immun., 67, 1461, 10.1128/IAI.67.3.1461-1470.1999 · DOI
- Mansouri, 2003, Clinical study to assess the immunogenicity and safety of a recombinant Pseudomonas aeruginosa OprF-OprI vaccine in burn patients, FEM Immunol. Med. Microbiol., 37, 161, 10.1016/S0928-8244(03)00072-5 · doi:10.1016/s0928-8244(03)00072-5
- Westritschnig, 2014, A randomized, placebo-controlled phase I study assessing the safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein OprF/I vaccine (IC43) in healthy volunteers, Hum. Vaccines Immunother., 10, 170, 10.4161/hv.26565 · DOI
- Rello, 2017, A randomized placebo-controlled phase II study of a Pseudomonas vaccine in ventilated ICU patients, Crit. Care, 21, 22, 10.1186/s13054-017-1601-9 · DOI
- Adlbrecht, 2020, Efficacy, immunogenicity, and safety of IC43 recombinant Pseudomonas aeruginosa vaccine in mechanically ventilated intensive care patients—a randomized clinical trial, Crit. Care, 24, 74, 10.1186/s13054-020-2792-z · doi:10.1186/s13054-020-2792-z
- Larbig, 2001, Safety and immunogenicity of an intranasal Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers, Vaccine, 19, 2291, 10.1016/S0264-410X(00)00550-8 · DOI
- Baumann, 2003, Mucosal vaccination with a recombinant OprF-I vaccine of Pseudomonas aeruginosa in healthy volunteers: Comparison of a systemic vs. a mucosal booster schedule, FEMS Immunol. Med. Microbiol., 37, 167, 10.1016/S0928-8244(03)00094-4 · DOI
- Baumann, 2007, Assessment of pulmonary antibodies with induced sputum and bronchoalveolar lavage induced by nasal vaccination against Pseudomonas aeruginosa: A clinical phase I/II study, Respir. Res., 8, 57, 10.1186/1465-9921-8-57 · DOI
- Lang, 2004, Vaccination of Cystic Fibrosis Patients Against Pseudomonas aeruginosa Reduces the Proportion of Patients Infected and Delays Time to Infection, Pediatr. Infect. Dis. J., 23, 504, 10.1097/01.inf.0000129688.50588.ac · DOI
- Zuercher, 2006, Cellular immunity in healthy volunteers treated with an octavalent conjugate Pseudomonas aeruginosa vaccine, Clin. Exp. Immunol., 142, 381, 10.1111/j.1365-2249.2005.02925.x · doi:10.1111/j.1365-2249.2005.02925.x
- Pier, 1987, Opsonophagocytic Killing Antibody to Pseudomonas aeruginosa Mucoid Exopolysaccharide in Older Noncolonized Patients with Cystic Fibrosis, N. Engl. J. Med., 317, 793, 10.1056/NEJM198709243171303 · doi:10.1056/nejm198709243171303
- Meluleni, 1995, Mucoid Pseudomonas aeruginosa growing in a biofilm in vitro are killed by opsonic antibodies to the mucoid exopolysaccharide capsule but not by antibodies produced during chronic lung infection in cystic fibrosis patients, J. Immunol., 155, 2029, 10.4049/jimmunol.155.4.2029 · DOI
- Mutharia, 1983, Surface localization of Pseudomonas aeruginosa outer membrane porin protein F by using monoclonal antibodies, Infect. Immun., 42, 1027, 10.1128/iai.42.3.1027-1033.1983 · DOI
- Knapp, 1995, Protection of immunocompromised mice against lethal infection with Pseudomonas aeruginosa by active or passive immunization with recombinant P. aeruginosa outer membrane protein F and outer membrane protein I fusion proteins, Infect. Immun., 63, 1855, 10.1128/iai.63.5.1855-1862.1995 · doi:10.1128/iai.63.5.1855-1862.1995
- Gabelsberger, 2000, Immunogenic efficacy of differently produced recombinant vaccines candidates against Pseudomonas aeruginosa infections, J. Biotechnol., 83, 3, 10.1016/S0168-1656(00)00311-4 · doi:10.1016/s0168-1656(00)00311-4
- Kaye, 2015, Infections Caused by Resistant Gram-Negative Bacteria: Epidemiology and Management, Pharmacother. J. Hum. Pharmacol. Drug Ther., 35, 949, 10.1002/phar.1636 · DOI · Paper page
- Sorichter, 2009, Immune responses in the airways by nasal vaccination with systemic boosting against Pseudomonas aeruginosa in chronic lung disease, Vaccine, 27, 2755, 10.1016/j.vaccine.2009.03.010 · DOI
- Sainz-Mejías, M., Jurado-Martín, I., and McClean, S. (2020). Understanding Pseudomonas aeruginosa–Host Interactions: The Ongoing Quest for an Efficacious Vaccine. Cells, 9. · DOI
- Baker, 2020, Immunological considerations in the development of Pseudomonas aeruginosa vaccines, Hum. Vaccines Immunother., 16, 412, 10.1080/21645515.2019.1650999 · DOI
- Lavoie, 2011, Innate immune responses to Pseudomonas aeruginosa infection, Microbes Infect., 13, 1133, 10.1016/j.micinf.2011.07.011 · DOI · Paper page
- Mauch, 2018, Mechanisms of humoral immune response against Pseudomonas aeruginosa biofilm infection in cystic fibrosis, J. Cyst. Fibros., 17, 143, 10.1016/j.jcf.2017.08.012 · DOI
- McIsaac, 2012, Toll-like receptors in the host defense against Pseudomonas aeruginosa respiratory infection and cystic fibrosis, J. Leukoc. Biol., 92, 977, 10.1189/jlb.0811410 · DOI
- Lin, 2017, Inflammation: A Double-Edged Sword in the Response to Pseudomonas aeruginosa Infection, J. Innate Immun., 9, 250, 10.1159/000455857 · DOI
- Jensen, 1993, Complement activation by Pseudomonas aeruginosa biofilms, Microb. Pathog., 15, 377, 10.1006/mpat.1993.1087 · doi:10.1006/mpat.1993.1087
- Johansen, 2004, Antibody response to Pseudomonas aeruginosa in cystic fibrosis patients: A marker of therapeutic success?—A 30-year Cohort study of survival in Danish CF patients after onset of chronic P. aeruginosa lung infection, Pediatric Pulmonol., 37, 427, 10.1002/ppul.10457 · DOI
- Jones, 2003, Inflammatory markers in cystic fibrosis patients with transmissible Pseudomonas aeruginosa, Eur. Respir. J., 22, 503, 10.1183/09031936.03.00004503 · DOI
- Hellfritzsch, M., and Scherließ, R. (2019). Mucosal Vaccination via the Respiratory Tract. Pharmaceutics, 11. · DOI
- Lavelle, 2022, Mucosal vaccines—Fortifying the frontiers, Nat. Rev. Immunol., 22, 236, 10.1038/s41577-021-00583-2 · DOI · Paper page
- Fan, 2019, Hydrogen peroxide-inactivated bacteria induces potent humoral and cellular immune responses and releases nucleic acids, Int. Immunopharmacol., 69, 389, 10.1016/j.intimp.2019.01.055 · DOI
- Ma, 2021, A novel inactivated whole-cell Pseudomonas aeruginosa vaccine that acts through the cGAS-STING pathway, Signal Transduct. Target. Ther., 6, 353, 10.1038/s41392-021-00752-8 · DOI
- Meynet, 2018, Killed but metabolically active Pseudomonas aeruginosa -based vaccine induces protective humoral- and cell-mediated immunity against Pseudomonas aeruginosa pulmonary infections, Vaccine, 36, 1893, 10.1016/j.vaccine.2018.02.040 · doi:10.1016/j.vaccine.2018.02.040
- Jing, 2020, Oligomerization of IC43 resulted in improved immunogenicity and protective efficacy against Pseudomonas aeruginosa lung infection, Int. J. Biol. Macromol., 159, 174, 10.1016/j.ijbiomac.2020.05.057 · DOI
- Ding, 2010, OprF/I-vaccinated sera inhibit binding of human interferon-gamma to Pseudomonas aeruginosa, Vaccine, 28, 4119, 10.1016/j.vaccine.2010.04.028 · doi:10.1016/j.vaccine.2010.04.028
- Kiyono, H., and Pascual, D.W. (2020). Mucosal Vaccines, Academic Press. [2nd ed.].
- Moyle, 2013, Modern Subunit Vaccines: Development, Components, and Research Opportunities, ChemMedChem, 8, 360, 10.1002/cmdc.201200487 · DOI · Paper page
- Moxon, 2019, Editorial: Reverse Vaccinology, Front. Immunol., 10, 2776, 10.3389/fimmu.2019.02776 · doi:10.3389/fimmu.2019.02776
- Rashid, 2017, Prediction of vaccine candidates against Pseudomonas aeruginosa: An integrated genomics and proteomics approach, Genomics, 109, 274, 10.1016/j.ygeno.2017.05.001 · DOI
- Bianconi, 2019, Genome-Based Approach Delivers Vaccine Candidates Against Pseudomonas aeruginosa, Front. Immunol., 9, 3021, 10.3389/fimmu.2018.03021 · DOI
- Day, 2019, Lectin activity of Pseudomonas aeruginosa vaccine candidates PSE17-1, PSE41-5 and PSE54, Biochem. Biophys. Res. Commun., 513, 287, 10.1016/j.bbrc.2019.03.092 · DOI
- Solanki, 2019, Prioritization of potential vaccine targets using comparative proteomics and designing of the chimeric multi-epitope vaccine against Pseudomonas aeruginosa, Sci. Rep., 9, 5240, 10.1038/s41598-019-41496-4 · DOI
- Wu, 2012, Th17-stimulating Protein Vaccines Confer Protection against Pseudomonas aeruginosa Pneumonia, Am. J. Respir. Crit. Care Med., 186, 420, 10.1164/rccm.201202-0182OC · DOI
- Mall, 2008, Role of Cilia, Mucus, and Airway Surface Liquid in Mucociliary Dysfunction: Lessons from Mouse Models, J. Aerosol Med. Pulm. Drug Deliv., 21, 13, 10.1089/jamp.2007.0659 · DOI · Paper page
- Baker, 2019, Intradermal vaccination with a Pseudomonas aeruginosa vaccine adjuvanted with a mutant bacterial ADP-ribosylating enterotoxin protects against acute pneumonia, Vaccine, 37, 808, 10.1016/j.vaccine.2018.12.053 · DOI
- Das, 2020, Development of a Broadly Protective, Self-Adjuvanting Subunit Vaccine to Prevent Infections by Pseudomonas aeruginosa, Front. Immunol., 11, 583008, 10.3389/fimmu.2020.583008 · DOI
- Gbian, D., and Omri, A. (2021). The Impact of an Efflux Pump Inhibitor on the Activity of Free and Liposomal Antibiotics against Pseudomonas aeruginosa. Pharmaceutics, 13. · doi:10.3390/pharmaceutics13040577
- Solleti, 2015, Antimicrobial properties of liposomal azithromycin for Pseudomonas infections in cystic fibrosis patients, J. Antimicrob. Chemother., 70, 784, 10.1093/jac/dku452 · DOI
- Heurtault, 2009, Design of a Liposomal Candidate Vaccine Against Pseudomonas aeruginosa and its Evaluation in Triggering Systemic and Lung Mucosal Immunity, Pharm. Res., 26, 276, 10.1007/s11095-008-9724-y · DOI
- Mayeux, 2021, Cell-free expression of the outer membrane protein OprF of Pseudomonas aeruginosa for vaccine purposes, Life Sci. Alliance, 4, e202000958, 10.26508/lsa.202000958 · DOI
- 2010, Naturally Produced Outer Membrane Vesicles from Pseudomonas aeruginosa Elicit a Potent Innate Immune Response via Combined Sensing of Both Lipopolysaccharide and Protein Components, Infect. Immun., 78, 3822, 10.1128/IAI.00433-10 · DOI · Paper page
- Li, 2021, Outer Membrane Vesicles Displaying a Heterologous PcrV-HitA Fusion Antigen Promote Protection against Pulmonary Pseudomonas aeruginosa Infection, mSphere, 6, e00699-21, 10.1128/mSphere.00699-21 · doi:10.1128/msphere.00699-21
- Li, 2021, Recombinant Pseudomonas Bionanoparticles Induce Protection against Pneumonic Pseudomonas aeruginosa Infection, Infect. Immun., 89, IAI0039621, 10.1128/IAI.00396-21 · DOI
- Micoli, 2020, Outer membrane vesicle vaccines, Semin. Immunol., 50, 101433, 10.1016/j.smim.2020.101433 · DOI · Paper page
- Bumann, 2010, Systemic, nasal and oral live vaccines against Pseudomonas aeruginosa: A clinical trial of immunogenicity in lower airways of human volunteers, Vaccine, 28, 707, 10.1016/j.vaccine.2009.10.080 · doi:10.1016/j.vaccine.2009.10.080
- Zhang, 2015, Salmonella Typhimurium strain expressing OprF-OprI protects mice against fatal infection by Pseudomonas aeruginosa, Microbiol. Immunol., 59, 533, 10.1111/1348-0421.12291 · doi:10.1111/1348-0421.12291
- McConnell, 2019, A Live Salmonella Vaccine Delivering PcrV through the Type III Secretion System Protects against Pseudomonas aeruginosa, mSphere, 4, e00116-19, 10.1128/mSphere.00116-19 · doi:10.1128/msphere.00116-19
- Chen, H., Ji, H., Kong, X., Lei, P., Yang, Q., Wu, W., Jin, L., and Sun, D. (2021). Bacterial Ghosts-Based Vaccine and Drug Delivery Systems. Pharmaceutics, 13. · DOI
- Sheweita, S.A., Amara, A.A., Gamal, H., Ghazy, A.A., Hussein, A., and Bahey-El-Din, M. (2022). Bacterial Ghosts of Pseudomonas aeruginosa as a Promising Candidate Vaccine and Its Application in Diabetic Rats. Vaccines, 10. · doi:10.3390/vaccines10060910
- Rodgers, 2018, Design and characterisation of a dissolving microneedle patch for intradermal vaccination with heat-inactivated bacteria: A proof of concept study, Int. J. Pharm., 549, 87, 10.1016/j.ijpharm.2018.07.049 · doi:10.1016/j.ijpharm.2018.07.049
- Cui, 2015, Mannose-modified chitosan microspheres enhance OprF-OprI-mediated protection of mice against Pseudomonas aeruginosa infection via induction of mucosal immunity, Appl. Microbiol. Biotechnol., 99, 667, 10.1007/s00253-014-6147-z · doi:10.1007/s00253-014-6147-z
- Najafzadeh, 2021, Immunological Properties of Exotoxin A Toxoid—Detoxified Lipopolysaccharide—Gold Nanoparticles Conjugate Against Pseudomonas aeruginosa Infection, Iran. J. Immunol., 18, 292
- Chen, 2018, Aluminum (oxy) Hydroxide Nanorods Activate an Early Immune Response in Pseudomonas aeruginosa Vaccine, ACS Appl. Mater. Interfaces, 10, 43533, 10.1021/acsami.8b18164 · doi:10.1021/acsami.8b18164
- Howlader, 2021, Effect of Two Unique Nanoparticle Formulations on the Efficacy of a Broadly Protective Vaccine Against Pseudomonas aeruginosa, Front. Pharmacol., 12, 2137, 10.3389/fphar.2021.706157 · doi:10.3389/fphar.2021.706157
- Shapouri, 2019, Exotoxin A-PLGA nanoconjugate vaccine against Pseudomonas aeruginosa infection: Protectivity in murine model, World J. Microbiol. Biotechnol., 35, 94, 10.1007/s11274-019-2669-y · DOI
- Azimi, 2021, Immunization against Pseudomonas aeruginosa using Alg-PLGA nano-vaccine, Iran. J. Basic Med Sci., 24, 476
- Gonzaga, 2022, Intranasal Delivery of Antigen-Coated Polymer Particles Protects against Pseudomonas aeruginosa Infection, ACS Infect. Dis., 8, 744, 10.1021/acsinfecdis.1c00434 · DOI
Cited by
Elfadadny, A., Ragab, R. F., AlHarbi, M., Badshah, F., Ibáñez-Arancibia, E., Farag, A., Hendawy, A. O., De los Ríos-Escalante, P. R., Aboubakr, M., Zakai, S. A., et al. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1374466 · Cited by 340
Elbehiry, A., Marzouk, E., Edrees, H. M., Ibrahem, M., Alzahrani, S., Anagreyyah, S., Abualola, H., Alghamdi, A., Alzahrani, A., Jaber, M., et al. (2026) · Microorganisms · doi:10.3390/microorganisms14010109 · Cited by 34
Badten, A. J., & Torres, A. G. (2024) · Vaccines · doi:10.3390/vaccines12030313 · Cited by 8
Metadata
- Authors
- Killough, M., Rodgers, A., & Ingram, R.
- Venue
- Vaccines
- Publisher
- MDPI AG
- Published
- 2022-07-08
- Volume
- 10
- Issue
- 7
- Pages
- 1100
- ISSN
- 2076-393X
- Cited by
- 93
- References
- 5
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pseudomonas aeruginosa: Recent Advances in Vaccine Development. https://app.cochat.ai/papers/10.3390/vaccines10071100
- The paper
- Killough, M., Rodgers, A., & Ingram, R. (2022). Pseudomonas aeruginosa: Recent Advances in Vaccine Development. Vaccines. https://doi.org/10.3390/vaccines10071100
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.